Huntington Ingalls Industries (HII) reports $3.1B Q2 revenue, backlog at $56.9B, with enhanced free cash flow guidance.

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response ...

Prior to her appointment at C3 Metals, Dr. Sykora worked as a highly sought after independent consultant with various companies in Canada, USA, Mexico and worldwide. She has held positions with First ...

Five local authorities have been rated non-compliant by the Regulator of Social Housing after “serious failings” on issues ...

As Lollapalooza returns to Chicago’s Grant Park this weekend, organizers are once again turning up the volume on ...

Airports across the UK are enforcing different 100ml liquid systems, threatening to cause hold-ups in security lanes as the ...

C3.ai (NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

C3.ai, Inc. AI is capitalizing on the booming demand for enterprise AI. However, the company now faces a critical challenge.

Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...